SynthesisFrontiers in medicine2026
Telitacicept for IgA nephropathy: a systematic review and meta-analysis of observational studies.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Telitacicept, a dual BAFF/APRIL inhibitor, is a potential targeted therapy for IgA nephropathy (IgAN), but its real-world efficacy and safety remain unclear. Methods: We systematically searched PubMed, Embase, Cochrane Central, ClinicalTrials.gov, CNKI, Wanfang, VIP, and SinoMed from inception to 2 March 2026 for observational studies of telitacicept in biopsy-confirmed IgAN. Eligible studies compared telitacicept monotherapy or telitacicept-based combination therapy with other immunosuppressive treatments. Outcomes included complete remission (CR), changes in 24-h urinary protein (Δ24hUPQ), estimated glomerular filtration rate (ΔeGFR), serum creatinine (ΔScr), albumin (ΔAlb), and adverse drug reactions (ADRs). Odds ratios (ORs) and mean differences (MDs) were pooled. Results: Eight observational studies involving 459 patients were included. Compared with other immunosuppressive therapies, telitacicept monotherapy showed no statistically significant differences in CR, Δ24hUPQ, ΔeGFR, ΔScr, and ΔAlb. Similarly, telitacicept-based combination therapy did not show statistically significant differences in CR, Δ24hUPQ, ΔeGFR, ΔScr, and ΔAlb. In terms of safety, telitacicept monotherapy was associated with a significantly lower incidence of ADRs than control treatments (OR 0.37, 95% CI 0.20-0.67). The certainty of evidence ranged from moderate to very low across outcomes. Conclusions: Current observational evidence suggests that telitacicept has a favorable safety profile and may offer clinical benefit in IgAN, particularly as a well-tolerated therapeutic option. Although superiority in efficacy outcomes was not statistically confirmed, the overall direction of effect tended to favor telitacicept in several analyses. Larger high-quality prospective studies are needed to further clarify its therapeutic value. Systematic review registration: The study was registered in the PROSPERO database (CRD420261296245), https://www.crd.york.ac.uk/PROSPERO/recorddashboard.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.